Nuvation Bio (NUVB) Price & Analysis

Compare

605 Followers

NUVB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.54 - $4.09

Previous CloseN/A

Volume977.37K

Average Volume (3M)7.31M

Market Cap

$1.28B

Enterprise Value$260.10M

Total Cash (Recent Filing)$607.72M

Total Debt (Recent Filing)$203.37M

Price to Earnings (P/E)―

Beta2.11

Next Earnings

Nov 05, 2025

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding342,272,740

10 Day Avg. Volume7,655,937

30 Day Avg. Volume7,310,654

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.20

Enterprise Value/Revenue18.12

Enterprise Value/Gross Profit65.78

Enterprise Value/Ebitda-1.25

Forecast

1Y Price Target

$9.60

Price Target Upside156.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Market OutlookResults from a recent oncologist survey point to a strong outlook for Ibtrozi given its favorable perceived clinical profile relative to competitors.

Regulatory ApprovalLead asset Ibtrozi has full FDA approval for ROS1+ NSCLC with a broad line-agnostic label, which could drive significant revenue.

Treatment GuidelinesThe National Comprehensive Cancer Network updated their guidance to add Nuvation Bio's Ibtrozi for both first-line and subsequent therapy in the treatment of ROS1+ Non-Small Cell Lung Cancer.

Bears Say

Market CompetitionPoorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.

Market SizeBear case highlights niche market and competitive threats with the ROS1 NSCLC being approximately 3K patients in the U.S.

Nuvation Bio News

Nuvation Bio enrolls first patient in TRUST-IV Phase 3 study of IBTROZI

Nuvation Bio (NUVB) announced it has enrolled the first patient in TRUST-IV, a Phase 3 study evaluating the...

14d ago

NUVB

Nuvation Bio initiated with a Buy at Jefferies

Jefferies analyst Farzin Haque initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $10 price target...

14d ago

NUVB

Nuvation Bio announces Japan MHLW approval for Ibtrozi

Nuvation Bio (NUVB) announced that Japan’s Ministry of Health, Labour and Welfare has approved Ibtrozi for the treatment...

25d ago

NUVB

Nuvation Bio’s Strategic Growth Potential and Promising Pipeline Justify Buy Rating

Farzin Haque, an analyst from Jefferies, has initiated a new Buy rating on Nuvation Bio (NUVB). Farzin Haque...

14d ago

NUVB

Nuvation Bio’s Phase 3 Study on Taletrectinib: A Potential Game-Changer for NSCLC Treatment

Nuvation Bio Inc (($NUVB)) announced an update on their ongoing clinical study. In a significant development for lung...

1M ago

NUVB

Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for Glioma Treatment

Nuvation Bio Inc (($NUVB)) announced an update on their ongoing clinical study. Nuvation Bio Inc. is conducting a...

1M ago

NUVB

Nuvation Bio announces new data from Phase 2 studies of IBTROZI

Nuvation Bio (NUVB) announced new and updated results from the Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI...

1M ago

NUVB

Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for IDH1 Mutant Glioma

Nuvation Bio Inc (($NUVB)) announced an update on their ongoing clinical study. Nuvation Bio Inc. is currently conducting...

2M ago

NUVB

Nuvation Bio’s Milestone with FDA Approval of IBTROZI

Nuvation Bio Inc ( ($NUVB) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

NUVB

Positive Market Trajectory and Promising Developments Drive Buy Rating for Nuvation Bio

TD Cowen analyst Yaron Werber has reiterated their bullish stance on NUVB stock, giving a Buy rating today....

2M ago

NUVB

Promising Outlook for Nuvation Bio: Buy Rating Backed by Ibtrozi’s Market Success and Future Prospects

JonesTrading analyst Soumit Roy has maintained their bullish stance on NUVB stock, giving a Buy rating on July...

2M ago

NUVB

Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma

Nuvation Bio Inc (($NUVB)) announced an update on their ongoing clinical study. Nuvation Bio Inc. is conducting a...

3M ago

NUVB

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with high growth...

3M ago

AURA

NUVB

Nuvation Bio management to meet virtually with B. Riley

Virtual Meeting to be held on July 9 hosted by B. Riley. Published first on TheFly – the...

3M ago

NUVB

NUVB FAQ

What was Nuvation Bio’s price range in the past 12 months?

Nuvation Bio lowest stock price was $1.54 and its highest was $4.09 in the past 12 months.

What is Nuvation Bio’s market cap?

Nuvation Bio’s market cap is $1.28B.

When is Nuvation Bio’s upcoming earnings report date?

Nuvation Bio’s upcoming earnings report date is Nov 05, 2025 which is in 22 days.

How were Nuvation Bio’s earnings last quarter?

Nuvation Bio released its earnings results on Aug 07, 2025. The company reported -$0.17 earnings per share for the quarter, the consensus estimate of -$0.17 by $0.

Is Nuvation Bio overvalued?

According to Wall Street analysts Nuvation Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nuvation Bio pay dividends?

Nuvation Bio does not currently pay dividends.

What is Nuvation Bio’s EPS estimate?

Nuvation Bio’s EPS estimate is -0.17.

How many shares outstanding does Nuvation Bio have?

Nuvation Bio has 342,272,740 shares outstanding.

What happened to Nuvation Bio’s price movement after its last earnings report?

Nuvation Bio reported an EPS of -$0.17 in its last earnings report, expectations of -$0.17. Following the earnings report the stock price went down -0.426%.

Which hedge fund is a major shareholder of Nuvation Bio?

Currently, no hedge funds are holding shares in NUVB

Nuvation Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-64.40%

Trailing 12-Months

Asset Growth

8.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nuvation Bio

Nuvation Bio (NUVB) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company operates within the pharmaceutical and biotechnology sectors and is dedicated to advancing a proprietary pipeline of novel oncology drug candidates. Nuvation Bio aims to address unmet medical needs by targeting multiple tumor types with its differentiated therapeutic approaches.

Nuvation Bio (NUVB) Earnings & Revenues

Historic Earnings Reports

NUVB Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlights significant progress towards the potential approval and launch of taletrectinib, underpinned by strong clinical data and a solid financial position. However, there are concerns about the increased net loss and potential challenges in achieving rapid market penetration.View all NUVB earnings summaries

NUVB Stock 12 Month Forecast

Average Price Target

$9.60

▲(156.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.7,4.338461538461539,4.976923076923077,5.615384615384616,6.253846153846155,6.892307692307693,7.5307692307692315,8.169230769230769,8.807692307692308,9.446153846153848,10.084615384615386,10.723076923076924,11.361538461538462,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.7,4.153846153846154,4.607692307692307,5.061538461538461,5.515384615384615,5.969230769230769,6.423076923076923,6.8769230769230765,7.3307692307692305,7.7846153846153845,8.23846153846154,8.692307692307692,9.146153846153846,{"y":9.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.7,3.876923076923077,4.053846153846154,4.230769230769231,4.407692307692308,4.584615384615384,4.7615384615384615,4.938461538461539,5.115384615384615,5.292307692307692,5.469230769230769,5.646153846153846,5.823076923076923,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >